Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Business Wire•08/11/2026•18:00 ET
6
Key Highlights
- ➤November 9, 2026 call will review topline 12-month Phase 3 ‘302’ results
- ➤Phase 3 ‘302’ evaluates VDPHL01 in over 500 males with pattern hair loss
- ➤VDPHL01 is an investigational extended-release oral minoxidil formulation in Phase 3 development
- ➤VDPHL01’s earliest expiring patent term is 2043
- ➤Pattern hair loss market projected to reach approximately $30 billion by 2028
Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Conference call will take place on Monday, November 9, 2026, at 8:00 am ET
Get started
Create a free account to read the full story.